Evaluation of apramycin activity against methicillin-resistant, methicillin-sensitive, and vancomycin-intermediate Staphylococcus aureus clinical isolates

Diagnostic Microbiology and Infectious Disease

Volumn 92, Issue 2, 2018, Pages 168-171

  Truelson, Katherine A ^a   Brennan Krohn, Thea ^b   Smith, Kenneth P ^b   Kirby, James E ^b  

^a BOSTON UNIVERSITY   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Activity spectrum; Aminoglycoside; Antibiotic; Apramycin; Gentamicin; Natural product; Repurposing; Staphylococcus aureus; Synergy

Indexed keywords

APRAMYCIN; DAPTOMYCIN; GENTAMICIN; LINEZOLID; VANCOMYCIN; ANTIINFECTIVE AGENT; METICILLIN; NEBRAMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG POTENTIATION; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MIC50; MIC90; NONHUMAN; PRIORITY JOURNAL; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; ANALOGS AND DERIVATIVES; DRUG EFFECT; HUMAN; METHICILLIN RESISTANCE; MICROBIOLOGY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; HUMANS; METHICILLIN; METHICILLIN RESISTANCE; NEBRAMYCIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 85048745736     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2018.05.018     Document Type: Article

References (44)

1. Akhi, M.T., Ghotaslou, R., Alizadeh, N., Pirzadeh, T., Beheshtirouy, S., Memar, M.Y., High frequency of MRSA in surgical site infections and elevated vancomycin MIC. Wound Med 17 (2017), 7–10, 10.1016/j.wndm.2017.01.002.
2. Bamberger, D.M., Boyd, S.E., Management of Staphylococcus aureus infections. Am Fam Physician 72 (2005), 2474–2481.
3. Bradley, A.J., Leach, K.A., Breen, J.E., Green, L.E., Green, M.J., Survey of the incidence and aetiology of mastitis on dairy farms in England and Wales. Vet Rec 160 (2007), 253–257.
4. Brennan-Krohn, T., Truelson, K.A., Smith, K.P., Kirby, J.E., Screening for synergistic activity of antimicrobial combinations against carbapenem-resistant Enterobacteriaceae using inkjet printer-based technology. J Antimicrob Chemother 72 (2017), 2775–2781, 10.1093/jac/dkx241.
5. Bruss, J.B., Lack of evidence associating nephrotoxicity with low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis. Clin Infect Dis, 49, 2009, 806, 10.1086/605287 [author reply 807-808].
6. Buchholtz, K., Larsen, C.T., Hassager, C., Bruun, N.E., Severity of gentamicin's nephrotoxic effect on patients with infective endocarditis: a prospective observational cohort study of 373 patients. Clin Infect Dis 48 (2009), 65–71, 10.1086/594122.
7. Buchholtz, K., Larsen, C.T., Schaadt, B., Hassager, C., Bruun, N.E., Once versus twice daily gentamicin dosing for infective endocarditis: a randomized clinical trial. Cardiology 119 (2011), 65–71, 10.1159/000329842.
8. Chen, C.Y., Nace, G.W., Irwin, P.L., A 6 x 6 drop plate method for simultaneous colony counting and MPN enumeration of campylobacter jejuni, listeria monocytogenes, and Escherichia coli. J Microbiol Methods 55 (2003), 475–479.
9. Clinical and Laboratory Standards Institute (CLSI), Methods for determining the bactericidal activity of antimicrobial agents; Approved guideline. CLSI document M-26A, 1999, Clinical and Laboratory Standards Institute, Wayne, PA.
10. Clinical and Laboratory Standards Institute (CLSI), Methods for Dilution Antimicrobial Suceptibility Tests for Bacteria that Grow Aerobically; Approved Standard. CLSI document M07-A10, 10th edition, 2015, Clinical and Laboratory Standards Institute, Wayne, PA.
11. Cosgrove, S.E., Vigliani, G.A., Fowler, V.G. Jr., Abrutyn, E., Corey, G.R., Levine, D.P. et al., Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 48 (2009), 713–721, 10.1086/597031.
12. Deleo, F.R., Otto, M., Kreiswirth, B.N., Chambers, H.F., Community-associated methicillin-resistant Staphylococcus aureus. Lancet 375 (2010), 1557–1568, 10.1016/S0140-6736(09)61999-1.
13. Deresinski, S., Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 49 (2009), 1072–1079, 10.1086/605572.
14. Dombrowski, J.C., Winston, L.G., Clinical failures of appropriately-treated methicillin-resistant Staphylococcus aureus infections. J Infect 57 (2008), 110–115, 10.1016/j.jinf.2008.04.003.
15. Fessler, A.T., Kadlec, K., Schwarz, S., Novel apramycin resistance gene apmA in bovine and porcine methicillin-resistant Staphylococcus aureus ST398 isolates. Antimicrob Agents Chemother 55 (2011), 373–375.
16. Frippiat, F., Chandrikakumari, K., Moutschen, M., Gentamicin in infective endocarditis: how to use it?. Clin Infect Dis 49 (2009), 320–321, 10.1086/600063 [author reply 321].
17. Hawkins, C., Huang, J., Jin, N., Noskin, G.A., Zembower, T.R., Bolon, M., Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes. JAMA Intern Med 167 (2007), 1861–1867.
18. Hazlewood, K.A., Brouse, S.D., Pitcher, W.D., Hall, R.G., Vancomycin-associated nephrotoxicity: grave concern or death by character assassination?. Am J Med, 123, 2010, 182.e1-7, 10.1016/j.amjmed.2009.05.031.
19. Herigstad, B., Hamilton, M., Heersink, J., How to optimize the drop plate method for enumerating bacteria. J Microbiol Methods 44 (2001), 121–129.
20. Jose, M.L.-N., Yaremi, Q., Laura, V., Ana, I.M., Francisco, J.L.-H., New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int 79 (2010), 33–45, 10.1038/ki.2010.337.
21. Kadlec, K., Ehricht, R., Monecke, S., Steinacker, U., Kaspar, H., Mankertz, J. et al., Diversity of antimicrobial resistance pheno- and genotypes of methicillin-resistant Staphylococcus aureus ST398 from diseased swine. J Antimicrob Chemother 64 (2009), 1156–1164, 10.1093/jac/dkp350.
22. Kang, A.D., Smith, K.P., Berg, A.H., Truelson, K.A., Eliopoulos, G.M., McCoy, C. et al., Efficacy of apramycin against multidrug-resistant Acinetobacter baumannii in the murine neutropenic thigh model. Antimicrob Agents Chemother, 62, 2018, e02585-02517.
23. Kang, A.D., Smith, K.P., Eliopoulos, G.M., Berg, A.H., McCoy, C., Kirby, J.E., In vitro apramycin activity against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 88 (2017), 188–191, 10.1016/j.diagmicrobio.2017.03.006.
24. Leber, A.L., Time-kill assay for determining synergy. Leber, A.L., (eds.) Clinical Microbiology Procedures Handbook, Fourth edition, 2016, ASM Press, Washington, D.C., 5.14.03.01–15.14.03.06.
25. Liu, C., Bayer, A., Cosgrove, S.E., Daum, R.S., Fridkin, S.K., Gorwitz, R.J. et al., Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52 (2011), e18–e55, 10.1093/cid/ciq146.
26. Livermore, D.M., Mushtaq, S., Warner, M., Zhang, J.C., Maharjan, S., Doumith, M. et al., Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother 66 (2011), 48–53, 10.1093/jac/dkq408.
27. Lodise, T.P., Lomaestro, B., Graves, J., Drusano, G.L., Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 52 (2008), 1330–1336.
28. Matt, T., Ng, C.L., Lang, K., Sha, S.-H., Akbergenov, R., Shcherbakov, D. et al., Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin. Proc Natl Acad Sci U S A 109 (2012), 10984–10989, 10.1073/pnas.1204073109.
29. Meyer, M., Freihofer, P., Scherman, M., Teague, J., Lenaerts, A., Böttger, E.C., In vivo efficacy of apramycin in murine infection models. Antimicrob Agents Chemother 58 (2014), 6938–6941, 10.1128/AAC.03239-14.
30. Naghili, H., Tajik, H., Mardani, K., Razavi Rouhani, S.M., Ehsani, A., Zare, P., Validation of drop plate technique for bacterial enumeration by parametric and nonparametric tests. Vet Res Forum 4 (2013), 179–183.
31. Odds, F.C., Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother, 52, 2003, 1, 10.1093/jac/dkg301.
32. Pillai, S.K., Moellering, R.C. Jr., Eliopoulos, G.M., Antimicrobial Combinations. Lorian, V., (eds.) Antibiotics in laboratory medicine, Fifth edition, 2005, Williams and Wilkins, Philadelphia, PA, 365–440.
33. RStudio, RStudio. 1.0.143 ed., 2017 [Boston, MA].
34. Schafer, J.A., Hovde, L.B., Rotschafer, J.C., Consistent rates of kill of Staphylococcus aureus by gentamicin over a 6-fold clinical concentration range in an in vitro pharmacodynamic model (IVPDM). J Antimicrob Chemother 58 (2006), 108–111, 10.1093/jac/dkl216.
35. Smith, K.P., Kirby, J.E., Verification of an automated, digital dispensing platform for at-will broth microdilution-based antimicrobial susceptibility testing. J Clin Microbiol 54 (2016), 2288–2293, 10.1128/JCM.00932-16.
36. Smith, K.P., Kirby, J.E., Evaluation of apramycin activity against carbapenem-resistant and -susceptible strains of Enterobacteriaceae. Diagn Microbiol Infect Dis 86 (2016), 439–441, 10.1016/j.diagmicrobio.2016.09.002.
37. Smith, K.P., Kirby, J.E., Validation of a high-throughput screening assay for identification of adjunctive and directly acting antimicrobials targeting carbapenem-resistant Enterobacteriaceae. Assay Drug Dev Technol 14 (2016), 194–206, 10.1089/adt.2016.701.
38. Steinkraus, G., White, R., Friedrich, L., Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–05. J Antimicrob Chemother 60 (2007), 788–794, 10.1093/jac/dkm258.
39. Tam, V.H., Kabbara, S., Vo, G., Schilling, A.N., Coyle, E.A., Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother 50 (2006), 2626–2631, 10.1128/AAC.01165-05.
40. Team, RC, R: A Language and Environment for Statistical Computing. 2017, R Foundation for Statistical Computing, Vienna, Austria.
41. Tong, S.Y.C., Davis, J.S., Eichenberger, E., Holland, T.L., Fowler, V.G., Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 28 (2015), 603–661, 10.1128/CMR.00134-14.
42. Turnbridge, J., Patterson, D.L., Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev 20 (2007), 391–408, 10.1128/CMR.00047-06.
43. Ziv, G., Bor, A., Sobagk, S., Elad, D., Nouws, J.F.M., Clinical pharmacology of apramycin in calves. J Vet Pharmacol Ther 8 (1985), 95–104, 10.1111/j.1365-2885.1985.tb00930.x.
44. Ziv, G., Kurtz, B., Risenberg, R., Glickman, A., Serum and milk concentrations of apramycin in lactating cows, ewes and goats. J Vet Pharmacol Ther 18 (1995), 346–351, 10.1111/j.1365-2885.1995.tb00602.x.